Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Campiani

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|September 28, 1998
New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structureG Campiani, V Nacci, S Bechelli, et al.
British Journal of Cancer|April 22, 2010
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivoS A Bright, A M McElligott, J W O'Connell, et al.
Journal of Medicinal Chemistry|August 28, 1999
Thiazolothiazepine inhibitors of HIV-1 integraseN Neamati, J A Turpin, H E Winslow, et al.
Journal of Medicinal Chemistry|November 2, 1999
Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT(3) receptor agonists: synthesis, further structure-activity relationships, and biological studiesG Campiani, E Morelli, S Gemma, et al.
Journal of Medicinal Chemistry|July 27, 2001
A rational approach to the design of selective substrates and potent nontransportable inhibitors of the excitatory amino acid transporter EAAC1 (EAAT3). new glutamate and aspartate analogues as potential neuroprotective agentsG Campiani, M De Angelis, S Armaroli, et al.
Antiviral Chemistry & Chemotherapy|May 20, 2000
Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalinylethylpyridylthioureas as potent antiviral agentsG Campiani, M Fabbrini, E Morelli, et al.
Journal of Medicinal Chemistry|August 30, 1996
Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligandsG Campiani, V Nacci, I Fiorini, et al.
Journal of Medicinal Chemistry|July 19, 1996
Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockersG Campiani, I Fiorini, M P De Filippis, et al.
British Journal of Cancer|December 24, 2010
PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cellsE N Maginn, P V Browne, P Hayden, et al.
The Journal of Biological Chemistry|September 27, 2001
The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitorsG Maga, A Ramunno, V Nacci, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|September 28, 1998
New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structureG Campiani, V Nacci, S Bechelli, et al.
British Journal of Cancer|April 22, 2010
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivoS A Bright, A M McElligott, J W O'Connell, et al.
Journal of Medicinal Chemistry|August 28, 1999
Thiazolothiazepine inhibitors of HIV-1 integraseN Neamati, J A Turpin, H E Winslow, et al.
Journal of Medicinal Chemistry|November 2, 1999
Pyrroloquinoxaline derivatives as high-affinity and selective 5-HT(3) receptor agonists: synthesis, further structure-activity relationships, and biological studiesG Campiani, E Morelli, S Gemma, et al.
Journal of Medicinal Chemistry|July 27, 2001
A rational approach to the design of selective substrates and potent nontransportable inhibitors of the excitatory amino acid transporter EAAC1 (EAAT3). new glutamate and aspartate analogues as potential neuroprotective agentsG Campiani, M De Angelis, S Armaroli, et al.
Antiviral Chemistry & Chemotherapy|May 20, 2000
Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalinylethylpyridylthioureas as potent antiviral agentsG Campiani, M Fabbrini, E Morelli, et al.
Journal of Medicinal Chemistry|August 30, 1996
Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligandsG Campiani, V Nacci, I Fiorini, et al.
Journal of Medicinal Chemistry|July 19, 1996
Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockersG Campiani, I Fiorini, M P De Filippis, et al.
British Journal of Cancer|December 24, 2010
PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cellsE N Maginn, P V Browne, P Hayden, et al.
The Journal of Biological Chemistry|September 27, 2001
The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitorsG Maga, A Ramunno, V Nacci, et al.
Pageof 4